期刊
JOURNAL OF VIROLOGY
卷 82, 期 18, 页码 9283-9287出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.01047-08
关键词
-
类别
资金
- National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [U19 AI-057319]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI057319] Funding Source: NIH RePORTER
Among 17 HLA-A2-positive healthy adults, CD8(+) T-cell responses against an HLA-A2-restricted matrix protein 1 (M1) epitope increased after immunization with trivalent inactivated influenza vaccine (TIV) in two individuals. The presence of M1 in TIV was confirmed by Western blotting. T-cell cytotoxicity assays showed that TIV is processed and the epitope is presented by antigen-presenting cells to an M1 epitope-specific CD8(+) T-cell line for specific lysis. These data show that TIV, which is formulated to contain surface glycoproteins to induce serotype-specific antibody responses, also contains M1, capable of inducing subtype cross-reactive CD8(+) T-cell responses in some vaccinees.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据